Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mersana Therapeutics, Inc. - Common Stock (NQ: MRSN )

0.5820 -0.0273 (-4.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mersana Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday
Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday. 
Via Benzinga
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
Via Benzinga
Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy
Via Benzinga
Recap: Mersana Therapeutics Q1 Earnings
Mersana Therapeutics (NASDAQ:MRSN) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Mersana Shares Climb As FDA Grants Fast Track Status To Triple-Negative Breast Cancer Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ: MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or... 
Via Benzinga
Mersana Therapeutics's Return On Capital Employed Insights
Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $4.28 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 10.5%, resulting in a loss of $52.22... 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2
U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday. 
Via Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. 
Via Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD.... 
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
  
Via Benzinga
Earnings Preview For Mersana Therapeutics
Mersana Therapeutics (NASDAQ:MRSN) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that Mersana... 
Via Benzinga
Earnings Scheduled For August 8, 2022
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter. 
Via Benzinga
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Mersana Therapeutics's Return On Capital Employed Overview
According to Benzinga Pro data, during Q1, Mersana Therapeutics (NASDAQ:MRSN) posted sales of $2.04 million. Earnings were up 3.52%, but Mersana Therapeutics still reported an overall loss of $47.26... 
Via Benzinga
Executives Buy Around $17M Of 5 Penny Stocks
The Nasdaq Composite index tumbled by more than 550 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their... 
Via Benzinga
Mersana Stock Gains On FDA Orphan Drug Designation For Gastric Cancer Drug
Mersana Therapeutics, Inc. (NASDAQ: MRSN) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its drug candidate XMT-2056 or the treatment of gastric cancer. The... 
Via Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.... 
Via Benzinga
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
68 Biggest Movers From Yesterday
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) shares rose 78.8% to $3.04 during Wednesday's pre-market session. The market value of their outstanding shares is at $19.2... 
Via Benzinga
Looking Into Mersana Therapeutics's Return On Capital Employed
Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 7.72%, resulting in... 
Via Benzinga
Recap: Mersana Therapeutics Q4 Earnings
Mersana Therapeutics (NASDAQ:MRSN) reported its Q4 earnings results on Monday, February 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback